联合西布曲明可减少使用伐尼克兰（Varenicline）戒烟引起的体重增加：初步研究
2010/02/23
前言：烟草戒断过程中的体重增加是戒烟的一大障碍。伐尼克兰是最为有效的戒烟药物，但不能阻止体重增加。如果联合使用西布曲明和伐尼克兰可以减少体重增加，则可促进戒烟。
方法：该研究旨在在使用伐尼克兰戒烟的女性中评价使用西布曲明预防体重增加的安全性和有效性。10例吸烟者纳入该开放标签的初步研究，使用西布曲明和伐尼克兰治疗12周。
结果：受试者对外观评价、健康定位、健康导向和身体满意度的自我评定较低。90％吸烟者报告，如果戒烟后体重增加自己会复吸。6例满足延长戒断标准的戒烟者，自基线到第12周（达到戒断后11周）的体重变化为0.2 +/- 1.3 kg。7天的点戒断率在第12周时为70％（95% CI 35%-93%）。
讨论：对于联合使用西布曲明和伐尼克兰预防戒烟带来的体重增加作为预防复吸的干预措施目前尚需更多的研究证实。
（陈欣 审校）
Nicotine Tob Res. 2009 Nov 11. [Epub ahead of print]
Sibutramine for weight gain attenuation during smoking cessation with varenicline: A pilot study.
Sood A, Ebbert JO, Clark MM, Croghan IT, Schroeder DR, Hays JT.
INTRODUCTION: Weight gain following tobacco abstinence is a significant barrier to cessation. Varenicline is the most effective medication for smoking cessation but does not prevent weight gain. Combining sibutramine and varenicline may facilitate smoking abstinence if weight gain is attenuated.
METHODS: Our aim was to assess the safety and efficacy of sibutramine for weight gain prevention among women quitting smoking with varenicline. Ten smokers enrolled in a pilot study of open-label sibutramine and varenicline for 12 weeks.
RESULTS: Participants rated themselves low on appearance evaluation, health evaluation, health orientation, and body-areas satisfaction. Ninety percent reported that they would return to smoking if they gained weight after stopping smoking. For the 6 subjects who met criteria for prolonged abstinence, weight change from baseline to Week 12 (11 weeks after the target quit date) was 0.2 +/- 1.3 kg, and the 7-day point-prevalence smoking abstinence rate at Week 12 was 70% (95% CI 35%-93%).
DISCUSSION: Combination therapy with sibutramine and varenicline for weight gain prevention and smoking cessation as an intervention for smokers at risk for relapse to smoking because of weight gain may warrant further investigation.
Sood A, Ebbert JO, Clark MM, et al. Nicotine Tob Res. 2009 Nov 11. [Epub ahead of print]
方法：该研究旨在在使用伐尼克兰戒烟的女性中评价使用西布曲明预防体重增加的安全性和有效性。10例吸烟者纳入该开放标签的初步研究，使用西布曲明和伐尼克兰治疗12周。
结果：受试者对外观评价、健康定位、健康导向和身体满意度的自我评定较低。90％吸烟者报告，如果戒烟后体重增加自己会复吸。6例满足延长戒断标准的戒烟者，自基线到第12周（达到戒断后11周）的体重变化为0.2 +/- 1.3 kg。7天的点戒断率在第12周时为70％（95% CI 35%-93%）。
讨论：对于联合使用西布曲明和伐尼克兰预防戒烟带来的体重增加作为预防复吸的干预措施目前尚需更多的研究证实。
（陈欣 审校）
Nicotine Tob Res. 2009 Nov 11. [Epub ahead of print]
Sibutramine for weight gain attenuation during smoking cessation with varenicline: A pilot study.
Sood A, Ebbert JO, Clark MM, Croghan IT, Schroeder DR, Hays JT.
INTRODUCTION: Weight gain following tobacco abstinence is a significant barrier to cessation. Varenicline is the most effective medication for smoking cessation but does not prevent weight gain. Combining sibutramine and varenicline may facilitate smoking abstinence if weight gain is attenuated.
METHODS: Our aim was to assess the safety and efficacy of sibutramine for weight gain prevention among women quitting smoking with varenicline. Ten smokers enrolled in a pilot study of open-label sibutramine and varenicline for 12 weeks.
RESULTS: Participants rated themselves low on appearance evaluation, health evaluation, health orientation, and body-areas satisfaction. Ninety percent reported that they would return to smoking if they gained weight after stopping smoking. For the 6 subjects who met criteria for prolonged abstinence, weight change from baseline to Week 12 (11 weeks after the target quit date) was 0.2 +/- 1.3 kg, and the 7-day point-prevalence smoking abstinence rate at Week 12 was 70% (95% CI 35%-93%).
DISCUSSION: Combination therapy with sibutramine and varenicline for weight gain prevention and smoking cessation as an intervention for smokers at risk for relapse to smoking because of weight gain may warrant further investigation.
Sood A, Ebbert JO, Clark MM, et al. Nicotine Tob Res. 2009 Nov 11. [Epub ahead of print]
上一篇：
口香糖对自我报告的尼古丁戒断的作用：是口味、咀嚼的作用？或是两者都有？
下一篇：
网络戒烟计划：可接受性及效果
